FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileCynata Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CYP.AX
Cynata Therapeutics Limited Stock AnalysisComprehensive stock analysis for Cynata Therapeutics Limited (CYP.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCYP.AX
CYP.AX
Cynata Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CYP.AX
  1. Home
  2. Stocks
  3. Cynata Therapeutics Limited

Cynata Therapeutics Limited

🇦🇺CYP.AX•ASX

Cynata Therapeutics Limited

🇦🇺CYP.AX•ASX

Your view on CYP.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Cynata Therapeutics Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Kilian Kelly
Headquarters
100 Cubitt Street, Cremorne, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Kilian Kelly
Headquarters
100 Cubitt Street, Cremorne, VIC, AU
Description

Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications.

Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds.

Furthermore, Cynata is advancing therapies for a broad spectrum of conditions such as asthma, heart attacks, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation.

Cynata maintains a crucial strategic alliance with Fujifilm, which is responsible for the clinical and commercial manufacturing and supply of its Cymerus therapeutic mesenchymal stem cell products.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Cynata Therapeutics Limited. Starting points for Cynata Therapeutics Limited: EPS -AUD 0.04, beta 1.12 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Cynata Therapeutics Limited. Cynata Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Cynata Therapeutics Limited. Trailing twelve-month EPS for Cynata Therapeutics Limited stands at -AUD 0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Cynata Therapeutics Limited. Cynata Therapeutics Limited has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CYP.AX12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
OCGNOcugen, Inc.HealthcareNASDAQ$250.8M
OCSOculis Holding AGHealthcareNASDAQ$456.2M
OCULOcular Therapeutix, Inc.HealthcareNASDAQ$1.3B
ODTXOdyssey Therapeutics, Inc.HealthcareNASDAQ$912.3M
OGENOragenics, Inc.HealthcareAMEX$852,760
OKUROnKure Therapeutics, Inc.HealthcareNASDAQ$114.2M
OKYOOKYO Pharma LimitedHealthcareNASDAQ$57.7M
OLMAOlema Pharmaceuticals, Inc.HealthcareNASDAQ$618.5M
OMEROmeros CorporationHealthcareNASDAQ$1.1B
ONCBeOne Medicines Ltd.HealthcareNASDAQ$43.1B
ONCOOnconetix, Inc.HealthcareNASDAQ$1.1M
ONCO.NEOnco-Innovations LimitedHealthcareNEO—
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Cynata Therapeutics Limited. Coverage tracks Cynata Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Cynata Therapeutics Limited.

CYP.AX AnalysisWeak
Past
1
Growth
1
Health
5
Profit
1
Value
1

News

Latest Market News